New Drug Development and Regulation From Pre-clinical to Clinical Trials

Foundations of FDA Regulation and the New Drug Development Process

The Bottom Line for Pharmaceutical Executives and Regulatory Affairs Managers:
The journey from a lead compound to an approved drug is governed by the rigorous standards of the FDA and the Code of Federal Regulations (CFR). Success in the 2026 regulatory environment requires a “Quality by Design” approach that begins in the pre-clinical stage. While GMP is not a formal obligation for early pre-clinical research the adherence to GLP and GDP is essential to ensure that your Investigational New Drug (IND) application survives retrospective FDA review. Establishing a neutral and robust Quality Assurance (QA) function early in the development lifecycle is the most effective way to safeguard your investment and ensure a seamless transition to human clinical trials.

The FDA (US Food and Drug Administration) was established in 1901 and evolved significantly following the 1938 Federal Food, Drug, and Cosmetic Act. Today the FDA protects public health by enforcing safety laws across five product-based centers including the Center for Drug Evaluation and Research (CDER) and the Center for Biological Evaluation and Research (CBER). Every new pharmaceutical must prove safety and efficacy before marketing approval is granted.

The Code of Federal Regulation (CFR) Framework

The FDA receives its authority from the US Congress to protect and promote public health. The US Code of Federal Regulations (CFR) codifies the general and permanent rules published in the Federal Register. Title 21 contains the specific regulations for Food and Drugs. Key sections include the following series:

Series 200 and 300 — Regulations for Pharmaceuticals
Series 600 — Regulations for Biological Products
Series 800 — Regulations for Medical Devices

FDA also publishes regulatory guidelines which reflect current thinking and serve as recommendations to the industry. While guidelines are not legally binding they assist manufacturers in interpreting the legal requirements of the law. Alternatively a justified risk-based approach may be used to interpret these regulations.

Pharmaceutical versus Biological Products

Understanding the distinction between CDER and CBER oversight is critical for correct regulatory positioning. CDER manages chemically synthesized products with known structures used to diagnose or treat disease. CBER oversees biological products derived from living sources such as humans, animals, or microorganisms. Since 2003 the FDA has restructured to ensure that expertise is coordinated across these centers. CDER handles the majority of prescription and generic drugs while CBER handles licenses under the Public Health Service Act.

The New Drug Development Lifecycle

New drug discovery is a prolonged process requiring high capital investment. It begins with drug discovery and screening which is now heavily supported by AI and bioinformatics to screen thousands of compounds. Once lead candidates are chosen the development moves into specific scientific stages.

1. Pre-Clinical Investigations

This stage involves in vitro and in vivo models to evaluate efficacy and safety. Researchers collect data regarding absorption, metabolism, extraction, and toxicity (ADME-Tox). Long-term animal studies analyze reproductive toxicity, carcinogenicity, and immunotoxicity across different species.

2. GLP and GMP Standards in Early Development

FDA requires Good Laboratory Practice (GLP) documentation for all safety studies according to 21 CFR part 58. This ensures that the data submitted is a true reflection of the results obtained. While formal GMP is not always mandatory for the earliest animal stages adhering to GxP principles provides higher levels of confidence for potential investors and during due diligence processes.

Pharmacodynamic and Pharmacokinetic Studies

Critical to the pre-clinical stage are PD and PK studies. PD studies analyze the effect of a drug on the body while PK studies analyze the effect of the body on the drug through the ADME process. The main purpose of these trials is to prove the investigational drug is safe and non-toxic prior to clinical stage initiation.

The Investigational New Drug Application (IND)

After the pre-clinical stage all data and a detailed human clinical trial plan are submitted to the FDA as part of the IND. If no response or “Clinical Hold” is received from the FDA within 30 calendar days the clinical trial can be initiated. The IND must include the following components:

Investigator Brochure with information on possible drug effects
Detailed study protocols and investigational plans
Chemistry Manufacturing and Controls (CMC) data
Animal pharmacology and toxicology results
FDA Form 1572 for every clinical investigator

International Equivalents — The EU CTA

For companies targeting the European market the Clinical Trial Application (CTA) is the equivalent of the US IND. A key difference in Europe is the requirement for a Qualified Person (QP) to approve the clinical batch release before the investigational drug can be used in trials. Both systems require strict informed consent as defined in 21 CFR part 50 and IRB review as defined in 21 CFR part 56.

Frequently Asked Questions

What is the difference between an FDA Law and an FDA Guidance?
Laws are codified in the CFR and are legally binding. Guidance documents reflect the current thinking of the FDA and are recommendations. You may follow an alternative approach if it is scientifically justified and risk-based.

Is GLP mandatory for all pre-clinical studies?
The FDA specifically requires GLP compliance for safety and toxicity studies. While not strictly required for basic efficacy or in vitro screening GLP is essential for the data used to support the safety profile in an IND.

How long do I have to wait after submitting an IND?
The FDA has a 30-day review period. If you do not receive a notification of a clinical hold within 30 calendar days you are legally permitted to begin your Phase 1 clinical trial.